Pruritus Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - GlaxoSmithKline, Chugai Pharma, Regeneron, Sanofi, DiverDrugs, Atridia, A

As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Pruritus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Pruritus Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pruritus Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Pruritus Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Pruritus Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pruritus treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pruritus market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Pruritus Therapeutics Domain:
https://www.delveinsight.com/report-store/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Route of Administration
Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Pruritus Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pruritus. Currently, GlaxoSmithKline is leading the therapeutics market with its Pruritus drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Pruritus Therapeutics Market Include:
- GlaxoSmithKline
- Chugai Pharmaceutical
- Regeneron
- Sanofi
- DiverDrugs
- Atridia
- Asana BioSciences
- Vanda Pharmaceuticals
- Pfizer
- Trevi Therapeutics
- AbbVie
- Lumosa Therapeutics
- Luye Pharma Group
And many others

Pruritus Drugs Covered in the Report Include:
- Linerixibat: GlaxoSmithKline
Further product details are provided in the report.

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Pruritus Current Treatment Patterns
4. Pruritus - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pruritus Late-Stage Products (Phase-III)
7. Pruritus Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pruritus Discontinued Products
13. Pruritus Product Profiles
14. Pruritus Key Companies
15. Pruritus Key Products
16. Dormant and Discontinued Products
17. Pruritus Unmet Needs
18. Pruritus Future Perspectives
19. Pruritus Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.